PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-35.33%
Cash & equivalents declining -35.33% while Medical - Pharmaceuticals shows 0.00% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-35.33%
Cash + STI yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of -0.78%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
5.48%
Receivables growth above 1.5x Medical - Pharmaceuticals median of 0.73%. Jim Chanos might see a serious red flag in ballooning receivables.
6.87%
Inventory growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
6.54%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-6.84%
Below half the Medical - Pharmaceuticals median of 0.00%. Jim Chanos would question if the company faces working capital strain.
3.57%
PP&E growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
-0.39%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-0.39%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
0.80%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
-0.80%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
6.73%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
3.65%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
50.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential red flags in big "other" asset lumps.
0.24%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
-3.43%
Payables growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
No Data
No Data available this quarter, please select a different quarter.
82.40%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
76.23%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a robust subscription base vs. peers.
-4.71%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-2.05%
Below half Medical - Pharmaceuticals median of 0.35%. Joel Greenblatt sees more conservative short-term leverage than peers.
-7.34%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.48%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-2.33%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-2.07%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects an alarming rise in overall leverage.
No Data
No Data available this quarter, please select a different quarter.
2.46%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees stronger retained profit growth vs. peers.
-2.56%
Above 1.5x Medical - Pharmaceuticals median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
2.59%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees stronger equity growth vs. peers.
0.24%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees more aggressive expansions than peers.
0.80%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
-5.67%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
45.90%
Above 1.5x Medical - Pharmaceuticals median 0.00%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.